| Biomarker ID | 1246 |
| PMID | 24240687 |
| Year | 2013 |
| Biomarker | N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Increased in Biochemical Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate Analysis: HR: [1.9 (95% CI: 1.1 - 3.4)] ; Multivariate Analysis: HR: [1.7 (95% CI: 0.9 - 3.1)] |
| Effect on Pathways | Pathways include: SGK494 human kinase ARCHS4 coexpression, SCYL3 human kinase ARCHS4 coexpression, AURKC human kinase ARCHS4 coexpression, BMPR1B human kinase ARCHS4 coexpression, RPS6KA5 human kinase ARCHS4 coexpression |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 252 patients with Prostate cancer were chosen out of which 101 experienced recurrence |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | 65.3% |
| Level Of Significance | Univariate: p = 0.0038; Multivariate: p =0.036 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NAALADL2 |